How could nanobody-based tri-specific CAR T cells improve the treatment of AML?

During the 2nd European CAR T Cell Meeting in Sitges, ES, the AML Global Portal was delighted to speak to Warren Hazelton, University College London, London, UK. We asked: How could nanobody-based tri-specific CAR T cells improve the treatment of AML?

Warren Hazelton explains the importance of understanding intra-tumor heterogeneity when treating patients. He talks about a new approach which aims to target up to three AML-associated antigens to overcome problems such as antigen negative escape. He also discusses the benefits of a small CAR construct